Introduction
============

Despite the significant advances made in the treatment of breast cancer in the past few decades, the prognosis for most patients with distant metastases remains poor.[@b1-cmar-10-5329]--[@b3-cmar-10-5329] A deep understanding of the molecular phenotype of distant metastasis is crucial to pave the way for the earlier detection of metastases and more effective treatments.[@b4-cmar-10-5329] The process by which cancer cells move from the primary site to distant organs through the bloodstream is not random.[@b5-cmar-10-5329] Instead, some types of cancer cells undergo a series of molecular programs that preferentially target specific organs and nest there.[@b6-cmar-10-5329]--[@b8-cmar-10-5329] This behavior of finding a destination involves the escape of the cancer cells from the primary tumor (sometimes referred to as "seeds") through the interaction with the microenvironment (or "soil") to the target organ.[@b5-cmar-10-5329]

Breast cancer subtypes (hormone receptor (HR^+^)/human epidermal growth factor receptor 2 (HER2^−^), HR^+^/HER2^+^, HR^−^/HER2^+^, and triple-negative \[HR^−^/HER2^−^\] subtypes) have been shown to have clinical utility in guiding therapeutic decisions.[@b4-cmar-10-5329],[@b9-cmar-10-5329] The decision whether to perform endocrine or HER2-targeted therapies is based primarily on the molecular subtype status of the tumor. Some studies have demonstrated that the molecular subtypes of breast cancer are closely related to the different risks of early recurrence and metastasis, response to treatment, and overall survival (OS).[@b9-cmar-10-5329],[@b10-cmar-10-5329]

The molecular characteristics of the primary tumor usually remain in the metastases.[@b9-cmar-10-5329],[@b11-cmar-10-5329] It has been reported that the genetic characteristics of the brain,[@b11-cmar-10-5329] lung,[@b12-cmar-10-5329] and bone[@b13-cmar-10-5329] metastases and the expression of HER2 and estrogen receptor (ER) in breast cancer are associated with increased risk of metastasis to specific organs. For example, subtypes of brain metastases are more likely to be HER2^+^ or triple-negative subtypes.[@b14-cmar-10-5329] To date, very few studies have evaluated the effect of molecular subtypes on specific metastatic sites. In particular, the distribution of molecular subtypes at different metastatic sites has been poorly understood. A better understanding of the mode of metastatic disease may affect adjuvant treatment and monitoring decisions and determine which screening and follow-up strategies are appropriate once breast cancer has been diagnosed.[@b15-cmar-10-5329]

The purpose of this study is to determine the association between molecular subtypes and metastatic patterns and their impact on prognosis based on a large real-world database, the Surveillance, Epidemiology and End Results (SEER) database.

Methods
=======

Data collection
---------------

The patients' data were extracted from the SEER database,[@b16-cmar-10-5329] which covers about 30% of the American population in 18 registries released in 2016. We obtained 312,035 patients diagnosed at 18 years old or above with primary and microscopically validated malignant breast cancer between January 1, 2010 and December 31, 2014 using SEER\*Stat software (version 8.3.4). Furthermore, those with unknown distant metastatic status were excluded from this population and we further excluded the patients diagnosed by death certificate or biopsy without active follow-up and whose survival record was zero months, leaving 295,213 patients in the entire cohort and generating a study cohort of 12,972 patients harboring distant metastases at first diagnosis of breast cancer. Before initiating this study, we submitted a data use agreement to the SEER program and were officially granted access to the database. The case listing comprised information on the following covariates: age, sex, race, marital status, insurance, molecular subtype, pathological grade, and distant metastatic sites. The Institutional Review Board of Sun Yat-sen University Cancer Center reviewed our study and waived the written consent forms because the patients could not be identified. We have obtained consents to publish this paper from all the participants of this study.

Statistical analysis
--------------------

Patients were categorized as the following breast cancer molecular subtypes: HR^+^/HER2^+^, HR^−^/HER2^+^, HR^+^/HER2^−^, triple-negative (HR^−^/HER2^−^), and unknown subtypes. The incidence proportion was defined as the percentage of patients with distant metastases at first diagnosis of breast cancer among the breast cancer population in each subset and computed after stratification by age, sex, race, etc. The patients were divided by age at diagnosis: \<40 years, 40--65 years, and \>65 years. Races were classified as white, black, Asian or Pacific Islander, and American Indian/Alaska Native in accordance with the database record.

We used multivariable logistic regression to estimate the ORs for subtypes which might be predictive for having a specific kind of distant metastases at first diagnosis of breast cancer. This model was adjusted for all potential influential factors, including age, sex, race, marital status, insurance, AJCC7 T stage, AJCC7 N stage, subtypes, pathological types, and grade. Distant metastasis refers to the bone, liver, lung, and brain metastases, apart from other metastatic sites including lymph node metastases.

We defined OS as the time from the first diagnosis of breast cancer to death due to breast cancer or other causes. Kaplan--Meier estimates of OS were plotted by subtype and the extent of systemic disease.

We calculated 95% CIs for all OR*s* across the subsets. A *P*-value of 0.05 or less was determined as statistically significant. All *P*-values were two-tailed. Statistical analysis was conducted using SPSS statistical software (SPSS IBM Statistics 21; IBM Corporation, Armonk, NY, USA). Apart from the subtype distribution calculation, figures and tables were produced by Excel software (Microsoft 2010). Line charts of median survival and Kaplan--Meier curves were plotted by SAS software (version 9.4; SAS Institute Inc., Cary, NC, USA) and GraphPad Prism 7 (GraphPad Software, Inc., La Jolla, CA, USA).

Results
=======

Of all patients diagnosed between 2010 and 2014, we identified 295,213 patients with invasive breast cancer from the SEER database according to the inclusion criteria ([Figure 1](#f1-cmar-10-5329){ref-type="fig"}). The average age of diagnosis was 61.68 years (median: 61 years). The prevalence of invasive breast cancer was 68.1% in HR^+^/HER2^−^ breast cancer patients (N*=*200,976), 9.53% in HR^+^/HER2^+^ breast cancer patients (N*=*28,150), 4.12% in HR^−^/HER2^+^ breast cancer patients (N*=*12,164), and 10.6% in triple-negative breast cancer patients (N*=*31,217) ([Table 1](#t1-cmar-10-5329){ref-type="table"}). Around 3.28% of newly diagnosed breast cancer patients at diagnosis had bone metastases (N*=*9,688), 1.52% had lung metastases (N*=*4,482), 1.20% had liver metastases (N=3,553), and 0.35% had brain metastases (N=1,045) ([Table 1](#t1-cmar-10-5329){ref-type="table"}). When patients were stratified by metastatic sites, there were statistical differences in age, race, marital status, insurance status, T-stage, N-stage, histology, tumor grade, and molecular subtype (all *P*\<0.05) ([Table 2](#t2-cmar-10-5329){ref-type="table"}).

Impact of molecular subtype on metastatic sites
===============================================

[Figure 2A](#f2-cmar-10-5329){ref-type="fig"} shows subtype distributions in patients with bone, lung, liver, and brain metastases in breast cancer patients at diagnosis, respectively ([Figure 2A](#f2-cmar-10-5329){ref-type="fig"}). The percentage of HR^+^/HER2^−^ subtype gradually decreased in patients presenting with bone (59.9%), lung (47.8%), liver (40.9%), and brain (38.8%) metastases compared with the cohort of all breast cancer patients (68.1%). The percentage of both HER2^+^ subtypes in the four metastatic sites increased, with the highest percentage in patients presenting with liver metastases (20.2% for HR^+^/HER2^+^, 13.1% for HR^−^/HER2^+^), compared with the entire cohort (9.53% for HR^+^/HER2^+^, 4.12% for HR^−^/HER2^+^). For the triple-negative subtype, the percentage of patients with bone metastases (8%) decreased compared to the entire cohort (10.6%). The proportion of visceral (lung, liver, and brain) metastases increased in the triple-negative subtypes, with the greatest increase in brain metastases (18.9%). In addition, this trend has been further verified in the patients with oligo-oran metastasis ([Figure 2B](#f2-cmar-10-5329){ref-type="fig"}). In addition, using a multivariable logistic regression model that adjusted for age, gender, race, insurance status, marital status, tumor size, and lymph node metastasis, it was found that patients with triple-negative and HER2^+^ subtypes had an increased risk of visceral (lung, liver, and brain) metastases, as shown in [Table 3](#t3-cmar-10-5329){ref-type="table"}. Compared with HR^+^/HER2^−^ tumors, both HER2^+^ subtypes were associated with significantly higher rates of liver, brain, and lung metastases, but their ORs gradually decreased in liver, brain, and lung metastases. Triple-negative tumors had a higher rate of brain (OR, 1.95 \[95% CI, 1.61--2.35\]), liver (OR, 1.35 \[95% CI, 1.20--1.51\]), and lung (OR, 1.34 \[95% CI, 1.21--1.47\]) metastases, but a significantly lower rate of bone metastases (OR, 0.64 \[95% CI, 0.59--0.69\]) than HR^+^/HER2^−^ tumors. In addition, older age (\>65 years) was associated with higher prevalence of lung metastases (OR, 1.75 \[95% CI, 1.52--2.02\]), but with lower liver metastases (OR, 0.69 \[95% CI, 0.61--0.79\]). Another interesting finding is that lobular cancer is associated with an increased risk of bone metastases (OR, 1.27 \[95% CI, 1.2--1.35\]), yet it is associated with a significant decrease in the risk of brain (OR, 0.65 \[95% CI, 0.51--0.83\]), lung (OR, 0.87 \[95% CI, 0.77--0.97\]), and liver (OR, 0.47 \[95% CI, 0.42--0.54\]) metastases.

Impact of subtypes on survival
------------------------------

Multivariable Cox analysis of OS according to metastatic sites is summarized in [Table 4](#t4-cmar-10-5329){ref-type="table"}. In all four kinds of distant metastases, HR^+^/HER2^+^ (vs HR^+^/HER2^−^) subtype is significantly associated with increased OS, while triple-negative subtype was significantly associated with a decreased OS. Compared with HR^+^/HER2^−^, HR^−^/HER2^+^ subtype is significantly associated with worse prognosis in patients with bone metastases (HR, 1.27 \[95% CI, 1.10--1.46\]) and lung metastases (HR, 1.30 \[95% CI, 1.11--1.52\]), but not in patients with liver and brain metastases (*P\>*0.05). The median survival of patients with specific metastatic status and active follow-up is stratified by subtypes and plotted in [Figure 3](#f3-cmar-10-5329){ref-type="fig"}. [Figure 4](#f4-cmar-10-5329){ref-type="fig"} shows the Kaplan--Meier survival curve. Brain metastases harbor the worst outcomes, while bone metastases the best (11 months vs 30 months, respectively). The triple-negative subtype predicted the worst prognosis for all metastases, with a median survival (IQR) of 6.0 (2.0--13.0), 10.0 (4.0--19.0), 9.0 (3.0--17.0), and 11.0 (4.0--20.0) months in brain, bone, liver, and lung metastases, respectively. In contrast, HER2^+^/HR^+^ cases show the best results among these metastatic sites, with an IQR of 25.0 (7.0--NR \[not reached\]), 41.0 (18.0--NR), 35.0 (12.0--NR), and 33.0 (15.0--NR) months, respectively.

Discussion
==========

To our knowledge, this study is by far the largest comprehensive analysis of the relationship between molecular subtypes and distant metastasis patterns while controlling for multiple clinical-pathological variables. In this analysis of 295,213 patients, we confirmed the hypothesis that the risk of site-specific metastasis is subtype dependent. This large sample size allows us to more accurately estimate the prevalence in each metastatic site after stratification by molecular subtypes, and to assess differences in survival outcomes at different metastatic sites.

Overall, the most common distant metastasis was bone metastases (3.28%), followed by lung (1.52%), liver (1.20%), and brain metastasis (0.35%). In the multivariate analysis, compared with HR^+^/HER2^−^ tumors, both HER2^+^ subtypes were associated with significantly higher rates of liver, brain, and lung metastases, but the ORs gradually decreased in liver, brain, and lung metastases. Triple-negative tumors had a higher rate of the brain (OR, 1.95), liver (OR, 1.35), and lung metastases (OR, 1.34) but a significantly lower rate of bone metastases (OR, 0.64) than HR^+^/HER2^−^ tumors. The prognosis of specific metastatic site varied with subtypes, with HR^+^/HER2^+^ subtypes being the best and triple-negative subtypes being the worst.

Previous studies have shown a significant difference in the time to distant recurrence.[@b9-cmar-10-5329],[@b17-cmar-10-5329] ER^−^ tumors are associated with early recurrence, whereas ER^+^ tumors are associated with a more than 5-year sustained late risk.[@b18-cmar-10-5329],[@b19-cmar-10-5329] Our study focused on distant metastases and found that patterns of metastasis were similar to that of early recurrence pattern of postoperative breast cancer. In our study, the risk of distant metastasis of HER2^+^ and triple-negative tumors was significantly increased. Previous studies have reported triple-negative breast cancer had a higher rate of brain metastasis in 6.2%--23.9% of patients;[@b9-cmar-10-5329],[@b20-cmar-10-5329],[@b21-cmar-10-5329] a rate of 18.7% of triple-negative tumors was found among patients with brain metastasis in this study. In previous studies, ER^−^/HER2^+^ tumors had a higher risk of brain metastases than ER^+^/HER2^−^ tumors.[@b22-cmar-10-5329]--[@b24-cmar-10-5329] Our research also confirmed this point.

There are also substantial differences in baseline characteristics according to metastatic sites. For example, the impact of age on different metastatic sites is heterogeneous. Young breast cancer cases appear to have a higher risk of bone metastases, but the difference was not statistically different. The risk of liver metastases decreases with age, but the risk of lung metastases increases with age. For brain metastases, patients aged 40--65 years were at higher risk than other age groups. Unlike the study by Kennecke et al,[@b9-cmar-10-5329] we found that larger tumor size (T3/4) was significantly associated with the incidence of distant metastases. The risk of bone metastases of lobular carcinoma is significantly higher than that of ductal carcinoma, but the risk of lung, liver, and brain metastases is reduced. The size of the primary tumor correlates with the prognosis of distant metastases, but there seems to be no significant correlation between regional lymph node metastasis and prognosis. These observations may reflect the impact of patient characteristics on the more aggressive disease tendencies.

This study confers several important implications for clinical practice. Firstly, breast cancer subtype can help identify patients at increased risk for specific metastatic sites. Secondly, the risk assessment of subtype-based site-specific metastasis can play an important role in the era of personalized medicine, and there is a need to work together to make advances in this area. In designing clinical trials, special attention should be paid to the matching of molecular subtypes and metastatic sites. A significant effect of molecular subtypes on distant metastases should also be considered during clinical examination or follow-up. Thirdly, our observations suggest that patients with bone metastases may have better survival outcomes, showing that these patients are more likely to benefit from primary tumor surgery.[@b25-cmar-10-5329]

This study harbors several limitations. Firstly, the details of the subsequent metastasis during follow-up are not yet clear as SEER database does not provide this data. Secondly, we were unable to gather information on molecular subtypes of metastatic lesions, which may provide insights into the effects of molecular subtypes on specific metastatic sites.[@b26-cmar-10-5329] Finally, we could not determine the exact location or number of each metastasis and the relevant information on treatment, so the impact of these factors on survival could not be obtained from our results.

Pre-emptive identification of patients at risk of distant metastases can improve the effectiveness of early diagnosis and interventions, and enhance the monitoring of the preferred location for metastasis in breast cancer patients. However, it was unclear whether breast cancer subtypes are associated with the risk of site-specific metastases. In this study, we apply by far the largest comprehensive analysis of the relationship between molecular subtypes and distant metastasis patterns while controlling for multiple clinical-pathological variables. In this analysis of 295,213 patients, we confirmed the hypothesis that the risk of site-specific metastasis is subtype dependent. This large sample size allows us to more accurately estimate the prevalence in each metastatic site after stratification by molecular subtypes, and to assess differences in survival outcomes at different metastatic sites. Our study can be further validated to assist clinical trial design and treatment and is of special importance for identifying patients at increased risk of site-specific metastases.

Conclusion
==========

Breast cancer subtypes are associated with different metastatic patterns and confer different prognostic impacts. Molecular subtypes can identify patients at increased risk of site-specific metastases.
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![Distribution (percentage) of molecular subtypes in all breast cancer patients, and in patients with bone, lung, liver, and brain metastases (**A**); distribution (percentage) of molecular subtypes in all breast cancer patients and in patients with oligo-organ metastases (**B**).\
**Abbreviations:** met, metastasis; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; +, denotes positive; −, denotes negative.](cmar-10-5329Fig2){#f2-cmar-10-5329}

![Median survival time (months) of different distant metastatic diseases stratified by molecular subtypes.\
**Abbreviations:** HER2, human epidermal growth factor receptor 2; HR, hormone receptor; +, denotes positive; −, denotes negative.](cmar-10-5329Fig3){#f3-cmar-10-5329}

![Kaplan--Meier survival curves and log-rank test results of different molecular subtypes in the brain (**A**), liver (**B**), lung (**C**), and bone (**D**) metastases.\
**Abbreviations:** HER2, human epidermal growth factor receptor 2; HR, hormone receptor; +, denotes positive; −, denotes negative.](cmar-10-5329Fig4){#f4-cmar-10-5329}

###### 

The incidence of patients with distant metastases was stratified by subtypes

  Subtypes              N (%)                                                         
  --------------------- ---------------- -------------- -------------- -------------- -------------
                                                                                      
  **HR^+^/HER2^−^**     200,976 (68.1)   5,799 (59.9)   2,144 (47.8)   1,452 (40.9)   405 (38.8)
  **HR^+^/HER2^+^**     28,150 (9.53)    1,319 (13.6)   598 (13.3)     717 (20.2)     164 (15.7)
  **HR^-^/HER2^+^**     12,164 (4.12)    507 (5.23)     381 (8.50)     464 (13.1)     112 (10.7)
  **Triple-negative**   31,217 (10.6)    775 (8.00)     712 (15.9)     474 (13.3)     195 (18.7)
  **Unknown**           22,706 (7.69)    1,288 (13.3)   647 (14.4)     446 (12.6)     169 (16.2)
  **All subtypes**      295,213 (100)    9,688 (100)    4,482 (100)    3,553 (100)    1,045 (100)

**Abbreviations:** HER2, human epidermal growth factor receptor 2; HR, hormone receptor; +, denotes positive; −, denotes negative; met, metastasis; N, number.

###### 

Clinicopathological and demographic characteristics of patients according to metastatic sites

  Variables                                                                  N (%)                                                       
  -------------------------------------------------------------------------- -------------- -------------- -------------- -------------- ---------------
                                                                                                                                         
  **Age at diagnosis (years)[a](#tfn2-cmar-10-5329){ref-type="table-fn"}**   60 (5.7)       325 (9.1)      229 (5.1)      622 (6.4)      835 (6.4)
   \<40                                                                      60 (5.7)       325 (9.1)      229 (5.1)      622 (6.4)      835 (6.4)
   40--65                                                                    675 (64.6)     2,116 (59.6)   2,340 (52.2)   5,431 (56.1)   7,123 (54.9)
   \>65                                                                      310 (29.7)     1,112 (31.3)   1913 (42.7)    3,635 (37.5)   5,014 (38.7)
  **Sex**                                                                                                                                
   Female                                                                    1,034 (98.9)   3,530 (99.4)   4,409 (98.4)   9,574 (98.8)   12,826 (98.9)
   Male                                                                      11 (1.1)       23 (0.6)       73 (1.6)       114 (1.2)      146 (1.1)
  **Race**                                                                                                                               
   White                                                                     767 (73.4)     2,641 (74.3)   3,261 (72.8)   7,484 (77.3)   9,853 (76)
   Black                                                                     207 (19.8)     636 (17.9)     851 (19)       1,498 (15.5)   2,168 (16.7)
   Asian or Pacific Islander                                                 63 (6.00)      241 (6.8)      316 (7.1)      612 (6.3)      819 (6.3)
   American Indian/Alaska Native                                             6 (0.6)        22 (0.6)       34 (0.8)       54 (0.6)       82 (0.6)
   Unknown                                                                   2 (0.2)        13 (0.4)       20 (0.4)       40 (0.4)       50 (0.4)
  **Marital status**                                                                                                                     
   Married                                                                   430 (41.1)     1,561 (43.9)   1,745 (38.9)   4,202 (43.4)   5,548 (42.8)
   Unmarried                                                                 557 (53.3)     1,780 (50.1)   2,464 (55)     4,959 (51.2)   6,706 (51.7)
   Unknown                                                                   58 (5.6)       212 (6)        273 (6.1)      527 (5.4)      718 (5.5)
  **Insurance**                                                                                                                          
   Insured                                                                   961 (92.0)     3,333 (93.8)   4,153 (92.7)   9,094 (93.9)   4,293 (33.1)
   Uninsured                                                                 65 (6.20)      144 (4.1)      225 (5)        397 (4.1)      6,677 (51.5)
   Unknown                                                                   19 (1.80)      76 (2.1)       104 (2.3)      197 (2)        2,002 (15.4)
  **T stage**                                                                                                                            
  T0-2                                                                       290 (27.8)     1,155 (32.5)   1,259 (28.1)   3,207 (33.1)   12,189 (94)
  T3-4                                                                       553 (52.9)     1,849 (52)     2,568 (57.3)   4,931 (50.9)   517 (4)
  **Unknown**                                                                202 (19.3)     549 (15.5)     655 (14.6)     1,550 (16)     266 (2.1)
  **N stage**                                                                                                                            
  N0                                                                         277 (26.5)     808 (22.7)     998 (22.3)     2,441 (25.2)   3,273 (25.2)
  N1                                                                         396 (37.9)     1,554 (43.7)   1,937 (43.2)   3,981 (41.1)   5,315 (41)
  N2--3                                                                      246 (23.5)     806 (22.7)     1,057 (23.6)   2,232 (23)     3,027 (23.3)
  **Unknown**                                                                126 (12.1)     385 (10.8)     490 (10.9)     1,034 (10.7)   1,357 (10.5)
  **Histology**                                                                                                                          
  Ductal                                                                     704 (67.4)     2,562 (72.1)   3,253 (72.6)   6,321 (65.2)   8,732 (67.3)
  Lobular                                                                    77 (7.4)       360 (10.1)     296 (6.6)      1,743 (18)     1,936 (14.9)
  Others                                                                     264 (25.3)     631 (17.8)     933 (20.8)     1,624 (16.8)   2,304 (17.8)
  **Grade**                                                                                                                              
  1--2                                                                       326 (31.2)     1,175 (33.1)   1,536 (34.3)   4,214 (43.5)   5,144 (39.7)
  3--4                                                                       427 (40.9)     1,591 (44.8)   1,910 (42.6)   3,108 (32.1)   4,764 (36.7)
  **Unknown**                                                                292 (27.9)     787 (22.2)     1,036 (23.1)   2,366 (24.4)   3,064 (23.6)
  **Subtypes**                                                                                                                           
  HR^+^/HER2^−^                                                              405 (38.8)     1,452 (40.9)   2,144 (47.8)   5,799 (59.9)   7,009 (54)
  HR^+^/HER2^+^                                                              164 (15.7)     717 (20.2)     598 (13.3)     1,319 (13.6)   1,826 (14.1)
  HR^−^/HER2^+^                                                              112 (10.7)     464 (13.1)     381 (8.5)      507 (5.2)      936 (7.2)
  Triple-negative                                                            195 (18.7)     474 (13.3)     712 (15.9)     775 (8)        1,450 (11.2)
  Unknown                                                                    169 (16.2)     446 (12.6)     647 (14.4)     1,288 (13.3)   1,751 (13.5)

**Notes:**

Unknown age was removed from model owing to non-convergence.

**Abbreviations:** HER2, human epidermal growth factor receptor 2; HR, hormone receptor; +, denotes positive; −, denotes negative; met, metastasis; N, number.

###### 

Multivariate logistic regression for metastatic sites among newly diagnosed breast cancer[a](#tfn4-cmar-10-5329){ref-type="table-fn"}

  Variables                                                                 OR (95% CI)                                                 
  ------------------------------------------------------------------------- ------------------- ------------------- ------------------- -------------------
                                                                                                                                        
  **Age at diagnosis, years[b](#tfn5-cmar-10-5329){ref-type="table-fn"}**                                                               
   \<40                                                                     1 \[Reference\]     1\[Reference\]      1 \[Reference\]     1 \[Reference\]
   40--65                                                                   1.39 (1.06--1.81)   0.80 (0.71--0.90)   1.29 (1.12--1.48)   NS
   \>65                                                                     NS                  0.69 (0.61--0.79)   1.75 (1.52--2.02)   NS
  **Sex**                                                                                                                               
   Female                                                                   1 \[Reference\]     1 \[Reference\]     1 \[Reference\]     1 \[Reference\]
   Male                                                                     NS                  NS                  1.76 (1.38--2.24)   1.30 (1.07--1.59)
   Race                                                                                                                                 
   White                                                                    1 \[Reference\]     1 \[Reference\]     1 \[Reference\]     1 \[Reference\]
   Black                                                                    1.23 (1.05--1.44)   1.19 (1.08--1.3)    1.28 (1.18--1.39)   1.11 (1.04--1.18)
   Asian or Pacific Islander                                                0.76 (0.59--0.99)   0.83 (0.72--0.95)   NS                  0.81 (0.74--0.88)
   American Indian/Alaska                                                   NS                  NS                  NS                  NS
   Native                                                                                                                               
   Unknown                                                                  NS                  0.49 (0.28--0.85)   NS                  0.53 (0.38--0.74)
  **Marital status**                                                                                                                    
   Married                                                                  1 \[Reference\]     1 \[Reference\]     1 \[Reference\]     1 \[Reference\]
   Unmarried                                                                1.46 (1.28--1.67)   1.34 (1.25--1.44)   1.51 (1.42--1.62)   1.41 (1.35--1.47)
   Unknown                                                                  NS                  NS                  1.23 (1.07--1.41)   NS
  **Insurance**                                                                                                                         
   Insured                                                                  1 \[Reference\]     1 \[Reference\]     1 \[Reference\]     1 \[Reference\]
   Uninsured                                                                2.04 (1.57--2.65)   1.4 (1.18--1.68)    2.06 (1.78--2.38)   1.73 (1.54--1.94)
   Unknown                                                                  0.61 (0.38--0.99)   0.74 (0.58--0.94)   NS                  0.65 (0.55--0.76)
  **T stage**                                                                                                                           
  T0-2                                                                      1 \[Reference\]     1 \[Reference\]     1 \[Reference\]     1 \[Reference\]
  T3-4                                                                      2.17 (1.88--2.50)   1.85 (1.71--1.99)   2.36 (2.20--2.52)   1.81 (1.73--1.89)
  Unknown                                                                   4.17 (3.30--5.27)   3.31 (2.88--3.79)   3.09 (2.72--3.51)   3.95 (3.62--4.3)
  **N stage**                                                                                                                           
  N0                                                                        1 \[Reference\]     1 \[Reference\]     1 \[Reference\]     1 \[Reference\]
  N1                                                                        3.45 (2.95--4.03)   4.73 (4.34--5.17)   5.37 (4.96--5.8)    4.79 (4.54--5.05)
  N2--3                                                                     5.21 (4.36--6.22)   6.04 (5.45--6.68)   7.29 (6.65--7.98)   7.18 (6.75--7.63)
  Unknown                                                                   5.01 (3.82--6.55)   8.35 (7.13--9.77)   8.55 (7.42--9.86)   8.51 (7.69--9.41)
  **Histology**                                                                                                                         
  Ductal                                                                    1 \[Reference\]     1 \[Reference\]     1 \[Reference\]     1 \[Reference\]
  Lobular                                                                   0.65 (0.51--0.83)   0.87 (0.77--0.97)   0.47 (0.42--0.54)   1.27 (1.2--1.35)
  Others                                                                    1.87 (1.57--2.23)   1.42 (1.28--1.59)   1.62 (1.48--1.77)   1.41 (1.32--1.52)
  **Grade**                                                                                                                             
  1--2                                                                      1 \[Reference\]     1 \[Reference\]     1 \[Reference\]     1 \[Reference\]
  3--4                                                                      1.34 (1.14--1.58)   1.50 (1.37--1.63)   1.50 (1.39--1.62)   1.19 (1.13--1.26)
  Unknown                                                                   3.25 (2.68--3.96)   3.03 (2.72--3.39)   3.15 (2.86--3.48)   3.59 (3.36--3.83)
  **Subtypes**                                                                                                                          
  HR^+^/HER2^−^                                                             1 \[Reference\]     1 \[Reference\]     1 \[Reference\]     1 \[Reference\]
  HR^+^/HER2^+^                                                             2.04 (1.69--2.47)   2.52 (2.29--2.78)   1.41 (1.28--1.55)   1.3 (1.22--1.39)
  HR^−^/HER2^+^                                                             2.61 (2.09--3.26)   3.17 (2.83--3.56)   1.66 (1.47--1.86)   NS
  Triple-negative                                                           1.95 (1.61--2.35)   1.35 (1.20--1.51)   1.34 (1.21--1.47)   0.64 (0.59--0.69)
  Unknown                                                                   1.26 (1.02--1.57)   1.11 (0.98--1.26)   1.07 (0.96--1.19)   0.83 (0.76--0.89)

**Notes:**

Only statistically significant results were presented (*P*\<0.05);

Unknown age was removed from model owing to non-convergence.

**Abbreviations:** +, denotes positive; −, denotes negative; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; NS, not significant.

###### 

Multivariable Cox analysis of OS according to metastatic sites[a](#tfn7-cmar-10-5329){ref-type="table-fn"}

  Variables                      Hazard ratio (95% CI)                                           
  ------------------------------ ----------------------- ------------------- ------------------- -------------------
                                                                                                 
  **Age (years) at diagnosis**                                                                   
   \<40                          1 \[Reference\]         1 \[Reference\]     1 \[Reference\]     1 \[Reference\]
   40--65                        1.72 (1.15--2.57)       1.50 (1.23--1.82)   1.35 (1.09--1.68)   1.34 (1.16--1.56)
   \>65                          2.76 (1.82--4.17)       2.60 (2.13--3.19)   2.02 (1.62--2.51)   2.06 (1.77--2.4)
  **Sex**                                                                                        
   Female                        1 \[Reference\]         1 \[Reference\]     1 \[Reference\]     1 \[Reference\]
   Male                          NS                      NS                  NS                  NS
  **Race**                                                                                       
   White                         1 \[Reference\]         1 \[Reference\]     1 \[Reference\]     1 \[Reference\]
   Black                         NS                      1.13 (1.00--1.27)   1.18 (1.06--1.31)   1.17 (1.08--1.27)
   Asian or Pacific Islander     NS                      NS                  NS                  NS
   American Indian/Alaska        NS                      NS                  NS                  NS
   Native                                                                                        
   Unknown                       NS                      NS                  NS                  NS
  **Marital status**                                                                             
   Married                       1 \[Reference\]         1 \[Reference\]     1 \[Reference\]     1 \[Reference\]
   Unmarried                     1.22 (1.03--1.43)       1.30 (1.18--1.43)   1.34 (1.23--1.46)   1.36 (1.28--1.45)
   Unknown                       1.66 (1.18--2.32)       NS                  NS                  NS
  **Insurance**                                                                                  
   Insured                       1 \[Reference\]         1 \[Reference\]     1 \[Reference\]     1 \[Reference\]
   Uninsured                     NS                      1.44 (1.15--1.80)   NS                  1.36 (1.17--1.57)
   Unknown                       NS                      NS                  NS                  NS
  **T stage**                                                                                    
  T0-2                           1 \[Reference\]         1 \[Reference\]     1 \[Reference\]     1 \[Reference\]
  T3-4                           NS                      1.13 (1.02--1.26)   NS                  1.17 (1.09--1.25)
  Unknown                        NS                      1.28 (1.1--1.48)    1.34 (1.17--1.54)   1.31 (1.19--1.44)
  **N stage**                                                                                    
  N0                             1 \[Reference\]         1 \[Reference\]     1 \[Reference\]     1 \[Reference\]
  N1                             NS                      0.87 (0.78--0.98)   NS                  NS
  N2--3                          NS                      NS                  NS                  NS
  Unknown                        NS                      NS                  NS                  1.16 (1.04--1.29)
  **Histology**                                                                                  
  Ductal                         1 \[Reference\]         1 \[Reference\]     1 \[Reference\]     1 \[Reference\]
  Lobular                        NS                      NS                  N S                 NS
  Others                         NS                      1.30 (1.13--1.49)   1.30 (1.17--1.46)   1.29 (1.18--1.41)
  **Grade**                                                                                      
  1--2                           1 \[Reference\]         1 \[Reference\]     1 \[Reference\]     1 \[Reference\]
  3--4                           NS                      1.18 (1.05--1.32)   1.41 (1.27--1.56)   1.37 (1.27--1.48)
  Unknown                        NS                      NS                  1.19 (1.05--1.36)   1.14 (1.04--1.25)
  **Subtypes**                                                                                   
  HR^+^/HER2^−^                  1 \[Reference\]         1 \[Reference\]     1 \[Reference\]     1 \[Reference\]
  HR^+^/HER2^+^                  0.74 (0.57--0.95)       0.67 (0.59--0.78)   0.85 (0.73--0.98)   0.85 (0.77--0.94)
  HR^−^/HER2^+^                  NS                      NS                  1.30 (1.11--1.52)   1.27 (1.10--1.46)
  Triple-negative                2.10 (1.68--2.62)       2.12 (1.86--2.42)   2.17 (1.93--2.44)   2.67 (2.42--2.95)
  Unknown                        1.61 (1.27--2.05)       1.21 (1.05--1.40)   1.56 (1.38--1.77)   1.39 (1.27--1.53)

**Notes:**

Only statistically significant results were presented (*P*\<.05).

**Abbreviations:** HER2, human epidermal growth factor receptor 2; HR, hormone receptor; NS, not significant; +, denotes positive; −, denotes negative.
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